Open Source Securities' investment strategy for the pharmaceutical industry in 2025: the long-term industry trend has not changed, focusing on sector stabilization and recovery.

At the current stage, the pharmaceutical policy tends to be stable, the rapidly growing unmet clinical needs under the background of aging, the continuous improvement of enterprise innovation capabilities, and other long-term industrial trends have not changed; at the same time, with the macroeconomic improvement, it is expected that the growth rate of medical insurance revenue suppressing the pharmaceutical sector will marginally increase.

Zhitong FinanceNov 18 15:04

topchoice medical (600763): operation steady, stable progress in new hospital expansion

Event: Recently, the company released its 2024 third-quarter performance report. From 2024 Q1 to Q3, the company achieved a revenue of 2.233 billion yuan, an increase of +2.21% year-on-year; achieving a net income attributed to the parent company of 0.498 billion yuan, a decrease of -2.

huaan SecuritiesNov 7 00:00

topchoice medical (600763): Short-term performance under pressure, waiting patiently for recovery.

Subject: The company released the third quarter report of 2024: In 2024 Q1-Q3, revenue reached 2.233 billion yuan (+2.21%), net income attributable to the parent company was 0.498 billion yuan (-2.63%), and net income deducted 0.494 billion yuan (-0.

Ping An SecuritiesNov 1 13:12

Topchoice Medical (600763): Performance meets expectations, dandelion hospital outpatient volume maintains rapid growth.

3Q24 performance meets our expectations. The company announced 3Q24 results: revenue of 0.823 billion yuan, a year-on-year increase of 0.04%; net income attributable to shareholders of 0.188 billion yuan (corresponding to earnings per share of 0.42 yuan), a year-on-year decrease of 9.10%.

China International Capital CorporationOct 31 00:00

Topchoice Medical (600763): Steady growth in performance for the first three quarters of 2024, rapid expansion in the planting business.

In the first three quarters of 2024, the performance grew steadily, with rapid growth in the planting business. In the first three quarters of 2024, the company achieved operating revenue of 2.233 billion yuan (+2.21% year-on-year, all figures below are on a year-on-year basis), with a net income attributable to the parent company of 0.498 billion.

Open Source SecuritiesOct 30 11:21

Topchoice Medical (600763): Income continues to grow, bullish on medium and long-term development

The company achieved revenue/net profit attributable to the mother of 223.3/49.8 billion yuan in 1-3Q24 (yoy +2.2%/-2.6%), of which revenue/net profit attributable to the mother was 82.3/18.8 billion yuan in 3Q24

htscOct 29 00:00